Notice: This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GEMP vs. VTYX, CNTX, LFVN, SCPH, GALT, SKYE, GBIO, RPTX, NVCT, and LLYShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Ventyx Biosciences (VTYX), Context Therapeutics (CNTX), LifeVantage (LFVN), scPharmaceuticals (SCPH), Galectin Therapeutics (GALT), Skye Bioscience (SKYE), Generation Bio (GBIO), Repare Therapeutics (RPTX), Nuvectis Pharma (NVCT), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Ventyx Biosciences Context Therapeutics LifeVantage scPharmaceuticals Galectin Therapeutics Skye Bioscience Generation Bio Repare Therapeutics Nuvectis Pharma Eli Lilly and Company Ventyx Biosciences (NASDAQ:VTYX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Is VTYX or GEMP more profitable? Ventyx Biosciences' return on equity of -61.43% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -61.43% -55.23% Gemphire Therapeutics N/A -419.70%-173.05% Do analysts recommend VTYX or GEMP? Ventyx Biosciences currently has a consensus target price of $8.29, suggesting a potential upside of 289.00%. Given Ventyx Biosciences' higher probable upside, analysts clearly believe Ventyx Biosciences is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has better valuation & earnings, VTYX or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$192.96M-$2.78-0.77Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Do insiders & institutionals believe in VTYX or GEMP? 97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in VTYX or GEMP? Gemphire Therapeutics received 259 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 69.98% of users gave Gemphire Therapeutics an outperform vote while only 47.62% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformVentyx BiosciencesOutperform Votes3047.62% Underperform Votes3352.38% Gemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Which has more risk and volatility, VTYX or GEMP? Ventyx Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Does the media favor VTYX or GEMP? In the previous week, Ventyx Biosciences' average media sentiment score of 0.67 beat Gemphire Therapeutics' score of 0.00 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Overall Sentiment Ventyx Biosciences Positive Gemphire Therapeutics Neutral SummaryVentyx Biosciences beats Gemphire Therapeutics on 6 of the 11 factors compared between the two stocks. Ad Porter & CompanyTicking time bomb. Detonation Nov 5Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.71M$6.74B$5.02B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A11.77128.7716.66Price / SalesN/A291.011,724.9679.31Price / CashN/A46.0936.9133.53Price / Book4.945.304.605.19Net Income-$23.64M$150.82M$114.09M$223.67M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$2.53-5.2%N/A+545.2%$37.63MN/A0.009Gap DownVTYXVentyx Biosciences2.7432 of 5 stars$2.39+3.5%$8.29+246.7%-86.2%$168.90MN/A-0.8673Positive NewsCNTXContext Therapeutics2.7789 of 5 stars$2.24-2.6%$6.25+179.0%+81.6%$168.00MN/A-2.117LFVNLifeVantage3.2069 of 5 stars$12.98-3.8%N/A+72.6%$164.86M$200.16M56.44260Earnings ReportHigh Trading VolumeSCPHscPharmaceuticals3.8694 of 5 stars$4.43+1.4%$18.00+306.3%-24.1%$159.72M$24.05M-2.8430GALTGalectin Therapeutics1.4918 of 5 stars$2.55+2.0%$11.00+332.2%+24.4%$158.50MN/A-3.229Upcoming EarningsPositive NewsSKYESkye Bioscience1.7065 of 5 stars$5.22+1.4%$18.67+257.6%+227.1%$158.36MN/A0.0011Upcoming EarningsGap UpGBIOGeneration Bio3.5121 of 5 stars$2.39+2.1%$7.50+213.8%+67.4%$156.17M$13.17M-1.00150Positive NewsRPTXRepare Therapeutics2.5715 of 5 stars$3.59-1.9%$10.00+178.6%-6.0%$152.38M$68.68M-2.19180Gap UpNVCTNuvectis Pharma1.8117 of 5 stars$7.87+0.4%$21.00+166.8%-32.9%$146.78MN/A-6.108Gap UpLLYEli Lilly and Company4.9808 of 5 stars$904.05+0.9%$1,013.41+12.1%+44.3%$859.21B$38.92B111.3443,000Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Ventyx Biosciences Competitors Context Therapeutics Competitors LifeVantage Competitors scPharmaceuticals Competitors Galectin Therapeutics Competitors Skye Bioscience Competitors Generation Bio Competitors Repare Therapeutics Competitors Nuvectis Pharma Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GEMP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
